Lonza Group AG (SWX:LONN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 33.39B -15.9% |
| Revenue (ttm) | 6.53B -1.6% |
| Net Income | -275.00M |
| EPS | -3.93 |
| Shares Out | 69.84M |
| PE Ratio | 36.83 |
| Forward PE | 26.23 |
| Dividend | 5.00 (1.05%) |
| Ex-Dividend Date | May 12, 2026 |
| Volume | 63,584 |
| Average Volume | 178,134 |
| Open | 478.10 |
| Previous Close | 478.10 |
| Day's Range | 471.70 - 478.90 |
| 52-Week Range | 454.60 - 594.80 |
| Beta | 0.82 |
| RSI | 38.41 |
| Earnings Date | Jul 22, 2026 |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanc... [Read more]
Financial Performance
Financial StatementsNews
Lonza Group AG Earnings Call Transcript: Q1 2026
Q1 saw strong performance across all CDMO platforms, with 2026 sales growth guided at 11%-12% CER and CORE EBITDA margin above 32%. Divestment of CHI and robust CapEx progress support a pure-play CDMO focus, while proactive risk management and healthy demand underpin the outlook.
Lonza: Q1 Performance In Line With Expectations; Confirms 2026 Outlook
(RTTNews) - Lonza (LONN.SW) reported a strong first quarter performance across its CDMO business in line with the expected trajectory for full year 2026. The company noted that, as expected, CER sales...
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Performance Research
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Performance Research
Simulations Plus enters funded research collaboration with Lonza, FDA
Simulations Plus (SLP) announced a funded research collaboration with Lonza Group (LZAGY) and the U.S. Food and Drug Administration to develop and validate a mechanistic, predictive framework for asse...
Lonza price target lowered to CHF 630 from CHF 680 at Berenberg
Berenberg lowered the firm’s price target on Lonza (LZAGY) to CHF 630 from CHF 680 and keeps a Buy rating on the shares.
Lonza Group AG Transcript: Investor update (Q&A)
A major portfolio transformation is complete with the divestment of 60% of CHI, focusing the business as a pure-play CDMO. Proceeds of at least CHF 3 billion will fund organic growth, bolt-on M&A, and a CHF 500 million share buyback, with 2026 guidance unchanged.
Lonza Group AG Transcript: Investor update
A major portfolio transformation is completed with the divestment of 60% of the CHI business, unlocking CHF 1.7 billion upfront and expected total proceeds of at least CHF 3 billion. Proceeds will fund organic growth, acquisitions, and a CHF 500 million share buyback, with the company now fully focused on its CDMO strategy and maintaining strong growth and margin outlooks.
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG
DALLAS & NEW YORK & LONDON & TOKYO--(BUSINESS WIRE)--Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the ...
RBC upgrades Lonza to Outperform, sees ‘higher-quality business’
As previously reported, RBC Capital analyst Charles Weston upgraded Lonza (LZAGY) to Outperform from Sector Perform with a price target of CHF 670, up from CHF 630. Lonza’s growth “algorithm”
Lonza upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Lonza (LZAGY) to Outperform from Sector Perform.
Lonza price target lowered to CHF 695 from CHF 753 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs lowered the firm’s price target on Lonza (LZAGY) to CHF 695 from CHF 753 and keeps a Buy rating on the shares. Published first on
Lonza Group AG Earnings Call Transcript: H2 2025
Delivered CHF 6.5 billion in sales (+21.7% constant currency), with core EBITDA margin up to 31.6% and free cash flow nearly doubling. Outlook for 2026 is 11%-12% sales growth and margin above 32%, supported by strong segment performance and disciplined capital allocation.
Lonza Group AG Transcript: 44th Annual J.P. Morgan Healthcare Conference
A clear strategy and robust financial model underpin strong growth, with major investments in global capacity and technology. The Vacaville acquisition strengthens U.S. presence, while ongoing regionalization and high customer retention support long-term value creation.
Lonza upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin upgraded Lonza (LZAGY) to Overweight from Equal Weight with a price target of SEK 650, up from SEK 625. Current share levels offer an attractive
Lonza Group AG Earnings Call Transcript: Q3 2025
Strong Q3 performance and robust contracting support confirmation of 2025 outlook, with CDMO sales growth of 20–21% and margin of 30–31%. Vacaville and CHI businesses are progressing as planned, and growth projects remain on track despite FX and funding headwinds.
Lonza price target raised to CHF 675 from CHF 650 at JPMorgan
JPMorgan raised the firm’s price target on Lonza (LZAGY) to CHF 675 from CHF 650 and keeps an Overweight rating on the shares.
Lonza price target raised to CHF 753 from CHF 744 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Lonza (LZAGY) to CHF 753 from CHF 744 and keeps a Buy rating on the shares.
Lonza Group AG Earnings Call Transcript: H1 2025
Delivered strong H1 2025 results with 19% CER sales growth and upgraded full-year CDMO guidance to 20%-21% sales growth and 30%-31% core EBITDA margin. Integrated Biologics and Advanced Synthesis drove performance, while CHI recovery and major CapEx projects progressed.
Lonza initiated with an Outperform at BNP Paribas Exane
BNP Paribas Exane analyst Odysseas Manesiotis initiated coverage of Lonza (LZAGY) with an Outperform rating and CHF 705 price target The company’s exposure is geared toward high growth niches, enablin...
Lonza Group AG Earnings Call Transcript: Q1 2025
Strong Q1 2025 performance supports a confirmed outlook for nearly 20% sales growth and a core EBITDA margin near 30%. Segment momentum is robust, with high asset utilization and ongoing growth projects, while risk from tariffs and FX is mitigated by global footprint and hedging.
Lonza price target lowered to CHF 630 from CHF 640 at RBC Capital
RBC Capital lowered the firm’s price target on Lonza (LZAGY) to CHF 630 from CHF 640 and keeps a Sector Perform rating on the shares.
Lonza price target lowered to CHF 670 from CHF 710 at Barclays
Barclays analyst Charles Pitman lowered the firm’s price target on Lonza (LZAGY) to CHF 670 from CHF 710 and keeps an Overweight rating on the shares.
Lonza price target raised to CHF 640 from CHF 610 at RBC Capital
RBC Capital raised the firm’s price target on Lonza (LZAGY) to CHF 640 from CHF 610 and keeps a Sector Perform rating on the shares.
Lonza downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin downgraded Lonza (LZAGY) to Equal Weight from Overweight with a CHF 625 price target The stock’s valuation is the high end of the historical range,
Lonza price target raised to CHF 710 from CHF 630 at Barclays
Barclays raised the firm’s price target on Lonza (LZAGY) to CHF 710 from CHF 630 and keeps an Overweight rating on the shares.